RCUS
USDArcus Biosciences Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$19.700
Kõrge
$20.500
Madal
$19.691
Maht
0.41M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
2.4B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.18M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Seotud uudised
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune
Goldman Sachs Maintains Neutral on Arcus Biosciences, Raises Price Target to $16
Goldman Sachs analyst Salveen Richter maintains Arcus Biosciences with a Neutral and raises the price target from $14 to $16.
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $56
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $54 to $56.
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $28
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences with a Buy and raises the price target from $24 to $28.
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late-line kidney
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $54
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences with a Buy and raises the price target from $47 to $54.
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support the ongoing
Seotud aktsiad
XPON
Expion360 Inc.
TPST
Tempest Therapeutics Inc.
GXAI
Gaxos.ai Inc.
CERS
Cerus Corporation
FTAIP
FTAI Aviation Ltd. 8.25% Fixed to Floating Rate Series A Cumulative Perpetual Redeemable Preferred Shares
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.